Titlebook: Clinical Applications of Immunotoxins; Arthur E. Frankel (Associate Professor of Medicine Book 1998 The Editor(s) (if applicable) and The

擔(dān)心

Introvert

Jocelyn Spence,Stuart Andrews,David Frohlich spread and deprivation of key nutrients, the goal of immunotoxin treatment is the direct killing of malignant cells. Because they are enzymatic proteins that act catalytically to kill cells, bacterial and plant toxins are often employed as the cell-killing component of immunotoxins. Here we provide

interior

Jocelyn Spence,Stuart Andrews,David Frohlichtimately die of their disease. The major reason for this poor outcome is the persistence or selection of cells which are refractory to conventional treatment. These cells might be eradicated by new immunotherapeutic agents with different modes of action. In this regard, monoclonal antibodies (Moabs)

假裝是你

植物群

變化無常

Tax Effects in Gilt-edged Security Valuationting of monoclonal antibodies chemically linked through a disulfide bond to a plant or bacterial toxin or radionuclide. Instability of the chemical conjugation of some of the earlier immunotoxins led to the concept of using protein engineering and recombinant DNA to assemble fusion genes combining t

連詞

squander

T. E. Cooke,J. Matatko,D. C. Staffordbacterial proteins with the tumor-specific binding capacity of monoclonal antibodies. Toxins such as ricin and diphtheria toxin have been linked to new cell surface binding moieties in order to target tumor cells for destruction. To the extent that tumor cells have cell surface receptors that distin

limber

吝嗇性

https://doi.org/10.1007/978-3-642-72153-3Bakterium; bacteria; clinical trial; clinical trials; immunotherapy; leukemia; lymphoma; pharmacology; poiso